Joseph Pavano
Optometrist · New Britain, CTNPI 1700851565
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,250 of the $21,617 with a category attached, or 79.8%. LKC Technologies, Inc. accounts for 80.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $17,714 and has fallen 97.6% since, to $427 in 2025. Among optometrist clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $317.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- LKC Technologies, Inc.$17K
- Novartis$649
- Bausch & Lomb Americas Inc.$599
- AbbVie$581
- Optos, Inc.$546
- Alcon$383
- plus $2K from 10 others
What the payments were for
- Speaking & faculty fees$17,25080%
- Food & beverage$4,32120%
- Entertainment$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| LKC Technologies, Inc. | 3 | $17,355 |
| Novartis | 22 | $649 |
| Bausch & Lomb Americas Inc. | 5 | $599 |
| AbbVie(2 entities) | 9 | $581 |
| Optos, Inc. | 2 | $546 |
| Alcon | 5 | $383 |
| Tarsus Pharmaceuticals, Inc. | 7 | $315 |
| Aerie Pharmaceuticals, Inc. | 2 | $249 |
| Shire North American Group Inc | 3 | $152 |
| Rxsight Inc | 2 | $147 |
| Oyster Point Pharma, Inc. | 2 | $145 |
| Sun Pharmaceutical Industries Inc. | 2 | $144 |
| Spark Therapeutics, Inc. | 1 | $125 |
| Johnson & Johnson Vision Care, Inc. | 1 | $122 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $80 |
| Amgen | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RETEVAL$17,250
- XIIDRA$606
- P200T$500
- MIEBO$500
- Rhopressa$249
- Rocklatan$249
- XDEMVY$247
- CEQUA$125
- VUITY$125
- Acuvue$122
- RESTASIS$117
- DURYSTA$116
- TRAVATAN Z$114
- LUMIGAN$112
- COMBIGAN$112
- TYRVAYA$112
- RXSIGHT CONTACT LENS$100
- RXSIGHT INJECTOR CARTRIDGE$100
- RXSIGHT INJECTOR HANDPIECE$100
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$100
How this compares
$21,617 in reported general payments places this provider in the 95th percentile of 574 optometrist providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 29 | $25,502 |
| RocklatanNetarsudil Mesylat/Latanoprost | 38 | $12,846 |
| LumiganBimatoprost | 34 | $12,350 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 28 | $7,968 |
| Travoprost | 16 | $2,355 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $1,771 |
| Latanoprost | 151 | $895 |
| Timolol Maleate | 43 | $556 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 13 | $451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $599 | $25,50229 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $249 | $12,84638 claims |
| AbbVieLumigan | $581 | $12,35034 claims |
| AlconSimbrinza | $383 | $7,96828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 574 optometrist providers in Connecticut.
Other optometrist in New Britain
- Mary FedusNew Britain$4K
- Joseph ThimonsFairfield$340K
- Inna LazarOld Greenwich$147K
- Jennifer StewartNew Canaan$91K
- Maria PribisStamford$78K
- Michael CooperWest Hartford$44K
- Susan JanikWest Hartford$20K
- Donald HigginsPlainville$18K
- Richard NowakEast Windsor$15K
- Barbara DuneHartford$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.